pyxisoncology.com (PYXS) Long-Term Debt to Capital Ratio

Pyxis Oncology Inc. - graphic logo of issuer PYXS

Pyxis Oncology, Inc. (PYXS) is establishing a precision treatment environment for malignant neoplasms by combining antibody developments with complex chemical formulas. This chart shows the market price is fixed at 1.31. The business relies on ADC technologies for the targeted destruction of pathologies in oncology centers, while research stability is guaranteed by a streamlined system for the rapid transport of biomaterials without logistical disruptions.

Long-Term Debt to Equity: Pyxis Oncology Inc. (PYXS) for 07/04/2022 - 10/30/2026

Analytical breakdowns for Pyxis Oncology, Inc.

- market price and analyst price targets:
Market Price Pyxis|PYXS - Price Target Chart
- market capitalization details:
Market Capitalization Pyxis Oncology, Inc.|PYXS - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Pyxis Oncology|PYXS - Company Book Value|Market-to-Book Ratio pyxisoncology.com|PYXS - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Pyxis Oncology, Inc.|PYXS - Long-Term Debt to Equity|Current Liabilities to Capital Pyxis|PYXS - Company Aggregate Debts|Debt to Net Assets Pyxis Oncology, Inc.|PYXS - Company Long-Term Liabilities|Short-Term Debt Pyxis Oncology|Intermediate Coverage Ratio pyxisoncology.com
- company profitability and valuation multiples indicators:
PYXS - Net Profit
Summary company analysis:PYXS - pyxisoncology.com
Brand item of Pyxis Oncology

The development of the closed scientific circuit of Pyxis Oncology, Inc. (PYXS) in the field of precision immuno-oncology requires significant capital expenditures for long-term protocols. By analyzing the ratio of long-term debt to equity, an investor assesses the share of borrowings exceeding one year within the financing structure, which determines the business's degree of dependence on external creditors and the overall financial stability of the company.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Compugen - Long-Term Debt to Equity Ratio|IO Biotech Inc. (IOBT) - Long-Term Liabilities to Capital|STRO: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc